Medicus Pharma Ltd. MDCX
Our company (formerly, Interactive Capital Partners Corporation) was incorporated pursuant to the Business Corporations Act (Ontario) on April 30, 2008 under the name Interactive Capital Partners Corporation.
On September 29, 2023, the Company completed a business combination (the "Business Combination") with SkinJect Inc. ("SkinJect"), a company existing under the laws of Pennsylvania. The Business Combination was completed pursuant to a business combination agreement dated May 12, 2023, as amended, among the Company, SkinJect and RBx Capital, LP ("RBx"), an investment entity owned and managed by Dr. Raza Bokhari, and resulted in a reverse takeover of the Company by the former shareholders of SkinJect, with SkinJect becoming a wholly owned operating subsidiary of the Company, and the Company being renamed "Medicus Pharma Ltd."
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| R&D | $7.7M | $3.5M | $193.6K | — |
| SG&A | $17.9M | $7.7M | $4.5M | — |
| Total operating expenses | $34.4M | $11.2M | $4.7M | — |
| Operating income | -$34.4M | -$11.2M | -$4.7M | — |
| Interest expense | $197.4K | $25.4K | — | — |
| Pre-tax income | -$47.3M | -$11.2M | -$5.3M | — |
| Income tax | $0 | $0 | $0 | — |
| Net income | -$47.3M | -$11.2M | -$5.3M | — |
| EPS, basic | -2.74 | -1.16 | -1.53 | — |
| EPS, diluted | -2.74 | -1.16 | -1.53 | — |
| Shares, diluted (wtd. avg.) | 17.3M | 9.6M | 3.5M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | $8.7M | $4.2M | $1.7M | $267.7K |
| Total current assets | $9.9M | $5.4M | $1.9M | — |
| Total assets | $10.1M | $5.6M | $1.9M | — |
| Accounts payable | $3.4M | $1.3M | $210.8K | — |
| Short-term debt | $5.2M | $0 | — | — |
| Total current liabilities | $9.9M | $2.3M | $781.6K | — |
| Total liabilities | $10.0M | $2.5M | $781.6K | — |
| Retained earnings | -$64.3M | -$28.9M | -$17.7M | — |
| Total equity | -$67.6K | $3.1M | $1.1M | -$12.2M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Operating cash flow | -$22.8M | -$10.2M | -$4.2M | — |
| Stock-based compensation | $1.5M | $713.1K | $98.6K | — |
| Investing cash flow | -$4.6M | $0 | — | — |
| Financing cash flow | $31.9M | $12.7M | $5.6M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001062993-26-002212.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Net income | — | -$5.3M | -$11.2M | -$47.3M |
Recent filings and events
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Material agreement signed Item 1.01
- New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
- Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
- Material agreement signed Item 1.01
- Delisting notice Item 3.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Material agreement signed Item 1.01
- Material agreement signed Item 1.01
- Unregistered share sale Item 3.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |